Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Katerina Klaskova"'
Autor:
Marie Lukasova, Katerina Klaskova, A. Sykorova, K Chroust, Vít Procházka, Jana Markova, J. Koren, Heidi Mocikova, L Buresova, David Belada, Lubica Gaherova, Pavla Stepankova
Publikováno v:
Leukemia Research. 90:106311
The optimal management of elderly patients (pts) with Hodgkin's lymphoma is not yet defined. The aims of the present study were: 1) to evaluate clinical and laboratory characteristics of elderly pts; 2) to indentify risk factors for unfavorable outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad5445056deb4fa0f3210fecf4646972
https://doi.org/10.1016/j.leukres.2020.106311
https://doi.org/10.1016/j.leukres.2020.106311
Autor:
Markus Dietlein, Tomas Kozak, Carsten Kobe, Deniz Kahraman, M. Skopalová, Hans-Theodor Eich, Katerina Dedeckova, Heidi Mocikova, Katerina Klaskova, Boris Böll, Jana Markova
Publikováno v:
Leukemia & Lymphoma. 53:64-70
The prognostic value of positron emission tomography (PET) in early therapy response assessment, after completion of chemotherapy and 3 months after the end of treatment in advanced Hodgkin lymphoma (HL) remains to be defined. We report the results o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59fa1988dc4c80b35c0d6efce5c3b185
https://doi.org/10.3109/10428194.2011.603444
https://doi.org/10.3109/10428194.2011.603444
Autor:
Tomas Kozak, Hans-Theodor Eich, K. Dedeckova, Markus Dietlein, Jana Markova, Annette Plütschow, Andreas Engert, Katerina Klaskova, M. Skopalova, Carsten Kobe
Publikováno v:
Annals of Oncology. 20:1270-1274
Background: As positron emission tomography (PET) seems to be a powerful prognostic marker in the treatment of Hodgkin's lymphoma (HL), we analysed the prognostic value of PET after four cycles of combination therapy with bleomycin, etoposide, doxoru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::487a286cc0e25151fce33fac7b0840d7
https://doi.org/10.1093/annonc/mdn768
https://doi.org/10.1093/annonc/mdn768
Autor:
David Belada, Tomas Kozak, Michael Doubek, Martin Spacek, Eduard Cmunt, Vít Procházka, Martin Simkovic, Irena Zygulova, Lukas Smolej, Monika Motyčková, Katerina Klaskova, Yvona Brychtová, Dagmar Adamova
Publikováno v:
ResearcherID
Background: Combination of fludarabine, cyclophosphamide and rituximab (FCR) is the current gold standard for physically fit patients (pts) with chronic lymphocytic leukemia (CLL). Nevertheless, many CLL patients cannot tolerate this intensive regime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc6327deea91170559e7f5870e6d5671
https://doi.org/10.1182/blood.v124.21.4670.4670
https://doi.org/10.1182/blood.v124.21.4670.4670
Autor:
Jana Marková, Heidi Mociková, Lubica Gaherová, Katerina Klásková, Maria Maco, Katerina Dedeckova, Tomas Kozak
Publikováno v:
HemaSphere, Vol 6, Pp 31-32 (2022)
Externí odkaz:
https://doaj.org/article/0ddf95de8f05436eb68690abe6f40c46
Autor:
Jiri Schwarz, Peter Rohon, Lukas Smolej, Katerina Klaskova, Tomas Kozak, Yvona Brychtová, Eduard Cmunt, Monika Motyčková, Michael Doubek, Martin Spacek, David Belada
Publikováno v:
ResearcherID
Abstract 2466 Background: Combination of fludarabine, cyclophosphamide and rituximab (FCR) is currently considered the treatment of choice in physically fit patients (pts) with chronic lymphocytic leukemia (CLL). However, many patients cannot tolerat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc5963da5c4cc504c85392b90843b09a
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000289662202689&KeyUID=WOS:000289662202689
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000289662202689&KeyUID=WOS:000289662202689
